Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMMG-HD5 trial in newly treated multiple myeloma
ISRCTN05745813Phase 3Completed
- Sponsor
- Heidelberg University
- Start
- Jan 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bortezomib and lenalidomide in multiple myeloma (MM) (4 arms), sponsored by Heidelberg University. Primary endpoints: Very good partial remission or better after induction therapy and Progression-free survival. Started Jan 2010; status: completed.
02
Drugs
bortezomiblenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN05745813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN05745813.